Literature DB >> 30849283

Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.

Carey Wexler Sherman1, Ravi Iyer2, Victor Abler2, Alexandria Antonelli3, Noelle E Carlozzi4.   

Abstract

Chorea, a hallmark symptom of Huntington's disease (HD), is characterized by jerky involuntary movements affecting the whole body that can interfere with daily functioning and impact health-related quality of life (HRQOL). To characterize chorea's impact on everyday functioning and HRQOL and identify patterns of perception and experiences of chorea among patients, caregivers, and providers. Data from focus groups of individuals with manifest HD (n = 8 early-stage HD; n = 16 late-stage HD), individuals at-risk or prodromal HD (n = 16), family HD caregivers (n = 17), and HD clinicians (n = 25). Focus group recordings were transcribed verbatim and analysed via constant comparison to identify meaningful and salient themes of living with chorea. Global themes of chorea's impact identified included: watching for chorea, experiences of stigma, and constraints on independence and relationships. Themes distinct to specific respondent groups included: Vigilance (at risk, prodromal); adaptation to chorea (early-stage); loss of autonomy and social life (late-stage); monitoring engagement (family caregivers) and safety (clinical providers). Living with chorea significantly constrains daily functioning, interactions, and HRQOL across the HD disease spectrum. Addressing these impacts via appropriate management of chorea can potentially enhance functioning, HRQOL, and overall satisfaction for persons with HD and their families.

Entities:  

Keywords:  Chorea; Huntington’s disease; focus groups; qualitative; quality of life

Mesh:

Year:  2019        PMID: 30849283      PMCID: PMC7685000          DOI: 10.1080/09602011.2018.1564675

Source DB:  PubMed          Journal:  Neuropsychol Rehabil        ISSN: 0960-2011            Impact factor:   2.868


  79 in total

1.  Deutetrabenazine for Treatment of Chorea in Huntington Disease.

Authors:  Michael D Geschwind; Nick Paras
Journal:  JAMA       Date:  2016-07-05       Impact factor: 56.272

2.  The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Authors:  Daniel Zielonka; Michał Ren; Giuseppe De Michele; Raymund A C Roos; Ferdinando Squitieri; Anna Rita Bentivoglio; Jerzy T Marcinkowski; G Bernhard Landwehrmeyer
Journal:  Parkinsonism Relat Disord       Date:  2018-01-05       Impact factor: 4.891

3.  Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures.

Authors:  Noelle E Carlozzi; Rebecca E Ready; Samuel Frank; David Cella; Elizabeth A Hahn; Siera M Goodnight; Stephen G Schilling; Nicholas R Boileau; Praveen Dayalu
Journal:  Mov Disord       Date:  2017-05-27       Impact factor: 10.338

4.  Fall risk assessment using the Tinetti mobility test in individuals with Huntington's disease.

Authors:  Anne D Kloos; Deb A Kegelmeyer; Gregory S Young; Sandra K Kostyk
Journal:  Mov Disord       Date:  2010-12-15       Impact factor: 10.338

5.  Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.

Authors:  Tatiana Yero; Jose A Rey
Journal:  P T       Date:  2008-12

Review 6.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

7.  Measuring depression after spinal cord injury: Development and psychometric characteristics of the SCI-QOL Depression item bank and linkage with PHQ-9.

Authors:  David S Tulsky; Pamela A Kisala; Claire Z Kalpakjian; Charles H Bombardier; Ryan T Pohlig; Allen W Heinemann; Adam Carle; Seung W Choi
Journal:  J Spinal Cord Med       Date:  2015-05       Impact factor: 1.985

8.  Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.

Authors:  David Victorson; Noelle E Carlozzi; Samuel Frank; Jennifer L Beaumont; Wendy Cheng; Brian Gorin; Mei Sheng Duh; David Samuelson; David Tulsky; Sandra Gutierrez; Cindy J Nowinski; Allison Mueller; Vivienne Shen; Victor Sung
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-04-14

9.  The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D.

Authors:  Julie Dorey; Emilie Clay; Amine Khemiri; Anis Belhadj; Patricia Trigo Cubillo; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2016-10-13

10.  Health-related quality of life and unmet healthcare needs in Huntington's disease.

Authors:  Marleen R van Walsem; Emilie I Howe; Gunvor A Ruud; Jan C Frich; Nada Andelic
Journal:  Health Qual Life Outcomes       Date:  2017-01-07       Impact factor: 3.186

View more
  2 in total

1.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

Review 2.  Social Withdrawal in Huntington's Disease: A Scoping Review.

Authors:  Jessie S Gibson; Kristen Springer
Journal:  J Huntingtons Dis       Date:  2022
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.